AMICUS THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
AMICUS THERAPEUTICS INC. - More news...
AMICUS THERAPEUTICS INC. - More news...
- SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
- WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
- WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
- ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions
- Thinking about buying stock in Applied UV, Fortress Biotech, Geovax Labs, Amicus Therapeutics, or Lucid Group?
- Thinking about buying stock in Grupo Televisa, Phunware, Immunitybio, Flexion Therapeutics, or Amicus Therapeutics?
-
Amicus Therapeutics, Inc. - FOLD Stock Chart Technical Analysis for 05-30-2019
-
Amicus Therapeutics, Inc. - FOLD Stock Chart Technical Analysis for 03-01-2019
- New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, and Expectations for 2019
- Amicus Therapeutics, Inc. to Host Earnings Call
- Analysis: Positioning to Benefit within Cummins, Macy's, Twenty-First Century Fox, Amicus Therapeutics, Crocs, and Rand Logistics — Research Highlights Growth, Revenue, and Consolidated Results
- Amicus Therapeutics, Inc. to Host Earnings Call
- Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call
- Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call
-
Amicus Therapeutics
- Amicus Therapeutics Announces Presentations and Posters at 13th Annual WORLDSymposium™ 2017
- Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance
- National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation for Galafold™ (migalastat) for Fabry Disease in England
- Amicus Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
- Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full of Option to Purchase Additional Notes
- Amicus Therapeutics Announces Pricing of Offering of Convertible Senior Notes
- Amicus Therapeutics Announces Proposed Offering of Convertible Senior Notes
- Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amicus Therapeutics, Inc. (FOLD)
- Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry Disease
- Journal of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study of Migalastat for Patients with Fabry Disease
- Amicus Therapeutics Announces Third Quarter 2016 Financial Results and Corporate Updates
- Amicus Therapeutics to Announce Third Quarter 2016 Financial Results on November 7, 2016
